Skip to main content

IGM Biosciences, Inc. (IGMS)

NASDAQ: IGMS · Delayed Price · USD
73.64 -1.18 (-1.58%)
Sep 20, 2021 4:00 PM EDT - Market closed
Market Cap2.40B
Revenue (ttm)n/a
Net Income (ttm)-115.25M
Shares Out33.37M
EPS (ttm)-3.58
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume133,196
Open73.05
Previous Close74.82
Day's Range71.37 - 74.78
52-Week Range42.00 - 133.00
Betan/a
AnalystsBuy
Price Target103.00 (+39.9%)
Est. Earnings DateNov 8, 2021

About IGMS

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L...

IndustryBiotechnology
IPO DateSep 18, 2019
Employees144
Stock ExchangeNASDAQ
Ticker SymbolIGMS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for IGMS stock is "Buy." The 12-month stock price forecast is 103.00, which is an increase of 39.87% from the latest price.

Price Target
$103.00
(39.87% upside)
Analyst Consensus: Buy

News

IGM Biosciences to Participate in Three Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today...

1 week ago - GlobeNewsWire

IGM Biosciences Announces Second Quarter 2021 Financial Results and Provides Corporate Update

– Recommended Phase 2 Dose of IGM-2323 Expected in 2021 –

1 month ago - GlobeNewsWire

IGM Biosciences Announces the Appointment of Chris H. Takimoto, M.D.

MOUNTAIN VIEW, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...

1 month ago - GlobeNewsWire

5 Mid-Cap Healthcare Stocks You'll Want on Your Radar for the 2nd Half of 2021

These biotech stocks could have great long-term potential.

Other symbols:EDITIONSXNCRZYME
1 month ago - The Motley Fool

IGM Biosciences Announces Expansion of IgM Platform into Infectious Diseases, Publication of Preclinical Data in Natu...

Company Expects to Advance First Intranasally Administered IgM Antibody, IGM-6268, into the Clinic in Third Quarter of 2021 Company Expects to Advance First Intranasally Administered IgM Antibody, IGM-6...

3 months ago - GlobeNewsWire

8 Stocks With The Highest Short Interest

Traders often look at short interest to get a sense of how many people are bearish on a stock and how strong the possibility of a short squeeze is. But simply looking at the size of the outstanding shor...

3 months ago - Benzinga

IGM Biosciences Announces First Quarter 2021 Financial Results and Provides Corporate Update

– Recommended Phase 2 Dose of IGM-2323 Expected in 2021 –

4 months ago - GlobeNewsWire

Resolutions at the Annual General Meeting in Medivir on 5 May 2021

HUDDINGE, Sweden, May 5, 2021 /PRNewswire/ -- Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director The annual general meet...

4 months ago - PRNewsWire

IGM Biosciences to Present at the Truist Securities Life Sciences Summit

MOUNTAIN VIEW, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today...

4 months ago - GlobeNewsWire

Medivir to participate at the Kempen Life Sciences Conference

STOCKHOLM, April 20, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)  today announces that the company will participate at the virtual meeting Kempen Life Sciences Conference - 2021 Thematic Vi...

5 months ago - PRNewsWire

Medivir appoints Magnus Christensen as interim CEO

STOCKHOLM, April 16, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that its Board of Directors appoints Magnus Christensen, the company's CFO, as interim CEO of Medivir. Magnu...

5 months ago - PRNewsWire

Medivir 2020 Annual Report published

STOCKHOLM, April 6, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2020 now is available at the company's website: www.medivir.com. In the spring of ...

5 months ago - PRNewsWire

Number of shares and votes in Medivir

STOCKHOLM, March 31, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during March 2021 as a result of the previously a...

5 months ago - PRNewsWire

IGM Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

– Recommended Phase 2 Dose for IGM-2323 Expected in 2021 –

5 months ago - GlobeNewsWire

Last patient with liver cancer included in the monotherapy part of Medivir's phase Ib study with MIV-818

STOCKHOLM, March 25, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the last patient with advanced liver cancer has been included in the first part of the phase Ib study w...

5 months ago - PRNewsWire

IGM Biosciences to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast o...

MOUNTAIN VIEW, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today...

5 months ago - GlobeNewsWire

Changes in Medivir's management and Board of Directors

STOCKHOLM, March 22, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that Yilmaz Mahshid leaves the position as CEO of Medivir. The nomination committee proposes that he is elec...

5 months ago - PRNewsWire

Resolution at the extraordinary general meeting in Medivir on 11 March 2021

HUDDINGE, Sweden, March 11, 2021 /PRNewswire/ -- Resolution on a directed issue of shares The extraordinary general meeting in Medivir Aktiebolag (publ) on 11 March 2021 resolved, in accordance with the...

6 months ago - PRNewsWire

Medivir to present at the H.C. Wainwright Global Life Sciences Conference

STOCKHOLM, March 8, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the virtual meeting H.C. Wainwright Global Life Sciences Conference, March 9...

6 months ago - PRNewsWire

Number of shares and votes in Medivir

STOCKHOLM, Feb. 26, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during February 2021 as a result of the previously...

6 months ago - PRNewsWire

IGM Biosciences to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day

MOUNTAIN VIEW, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...

7 months ago - GlobeNewsWire

Medivir enters into exclusive licensing agreement with IGM Biosciences for birinapant

STOCKHOLM, Jan. 12, 2021 /PRNewswire/ -- Medivir AB (publ) (Nasdaq Stockholm: MVIR) today announced that it has entered into an exclusive licensing agreement, through which IGM Biosciences, Inc. (Nasdaq...

8 months ago - PRNewsWire

IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant

- IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors - - IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors -

8 months ago - GlobeNewsWire

IGM Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...

8 months ago - GlobeNewsWire

This Biotech Skyrocketed 84% in 2 Days, But Is It Warranted?

Short squeezes don't typically live up to their expectations.

8 months ago - The Motley Fool